Key Developments For ImmunoGen, Inc.
ImmunoGen, Inc. (IMGN.O) (Consolidated Issue listed on NASDAQ Global Market)
ImmunoGen, Inc. Announces Second License Taken By Amgen For Right To Use TAP Technology
ImmunoGen, Inc. announced that Amgen Inc. has licensed the exclusive right to use the Company`s maytansinoid Targeted Antibody Payload (TAP) technology to develop anticancer therapeutics to an undisclosed target.
ImmunoGen, Inc. Announces Encouraging Clinical Data With IMGN901 Compound In Treatment Of Merkel Cell Carcinoma
ImmunoGen, Inc. announced encouraging clinical data with its IMGN901 product candidate in the treatment of Merkel cell carcinoma (MCC). Meaningful evidence of anticancer activity has been noted among the limited number of patients with MCC who have received IMGN901. IMGN901 is designed to kill cancer cells that express CD56, a protein. It consists of a CD56-binding antibody with a potent cancer-cell killing agent, DM1, attached to it using an engineered linker. IMGN901 is a potential treatment for MCC, small-cell lung cancer, multiple myeloma, ovarian cancers and other CD56+ tumors. It is in Phase I testing for the treatment of CD56+ solid tumors and multiple myeloma. The compound is wholly-owned by ImmunoGen. All of the patients had received prior chemotherapy regimens for their cancer and entered the clinical trial, Study 002, with metastatic disease. Two of these six patients had a marked, objective response to treatment with IMGN901, while a third patient had clinically relevant stable disease for this patient population: One patient had a partial response (PR) after the first IMGN901 treatment cycle and reached a complete response (CR) by the end of the third treatment cycle. This patient has been in remission for more than four years; A second patient had marked tumor reduction after the first IMGN901 treatment cycle, but declined further therapy due to the occurrence of an adverse event.
ImmunoGen, Inc. Names Board Chairman-The Boston Globe
The Boston Globe reported that ImmunoGen, Inc. has named Stephen C. McCluski as Board Chairman, replacing former Chief Executive Mitchel Sayare.
ImmunoGen, Inc. Reiterates FY 2010 Earnings Outlook
ImmunoGen, Inc. announced that for fiscal 2010, it expects net loss to be between $44-$47 million. According to Reuters Estimates, analysts were expecting the Company to report net loss of $44 million for the same period.
ImmunoGen, Inc. Announces Amgen Inc Has Licensed Rights To Use TAP Technology For Solid Tumor Target
ImmunoGen, Inc. announced that Amgen Inc. has licensed the exclusive right to use the Company`s maytansinoid Targeted Antibody Payload (TAP) technology to develop anticancer therapeutics to an undisclosed target found on solid tumors. This license was taken under an agreement established in 2000 between ImmunoGen and Abgenix, Inc., which later was acquired by Amgen. Under the terms of the license, ImmunoGen receives a $1 million license payment upfront. The Company also is entitled to receive milestone payments potentially totaling $34 million plus royalties on the sales of any resulting products. Amgen is responsible for the development, manufacturing, and marketing of any products resulting from this license.
